Kura Oncology Stock Performance
| KURA Stock | USD 11.17 0.42 3.91% |
The company secures a Beta (Market Risk) of 0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kura Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kura Oncology is expected to be smaller as well. At this point, Kura Oncology has a negative expected return of -0.82%. Please make sure to verify Kura Oncology's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Kura Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.91 | Five Day Return 8.76 | Year To Date Return (27.28) | Ten Year Return (25.53) | All Time Return (25.53) |
1 | Acquisition by Vasconcelles Michael of 17333 shares of Kura Oncology at 20.88 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 594 shares by Thomas Doyle of Kura Oncology at 17.8005 subject to Rule 16b-3 | 09/26/2024 |
3 | Acquisition by Thomas Doyle of 21250 shares of Kura Oncology subject to Rule 16b-3 | 10/11/2024 |
4 | Acquisition by Collins Helen Louise of 46000 shares of Kura Oncology at 18.98 subject to Rule 16b-3 | 10/15/2024 |
5 | Acquisition by Bair Teresa Brophy of 46250 shares of Kura Oncology subject to Rule 16b-3 | 10/22/2024 |
6 | Kura Oncologys Outperform Rating Reiterated at Wedbush | 11/07/2024 |
7 | Acquisition by Wilson Troy Edward of 300000 shares of Kura Oncology subject to Rule 16b-3 | 11/08/2024 |
8 | Paradigm Biocapital Advisors LP Adjusts Stake in Kura Oncology Inc | 11/15/2024 |
9 | Kura stock slides 17 percent on Kyowa Kirin deal for ziftomenib | 11/20/2024 |
10 | Kura Oncology stock gains momentum as Jefferies sees potential menin leadership | 11/21/2024 |
11 | Biomea Fusions SWOT analysis clinical hold impacts diabetes drug stock | 11/26/2024 |
| Begin Period Cash Flow | 51.8 M |
Kura |
Kura Oncology Relative Risk vs. Return Landscape
If you would invest 2,106 in Kura Oncology on August 30, 2024 and sell it today you would lose (989.00) from holding Kura Oncology or give up 46.96% of portfolio value over 90 days. Kura Oncology is currently does not generate positive expected returns and assumes 5.226% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Kura, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kura Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kura Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kura Oncology, and traders can use it to determine the average amount a Kura Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1564
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KURA |
Estimated Market Risk
| 5.23 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.82 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kura Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kura Oncology by adding Kura Oncology to a well-diversified portfolio.
Kura Oncology Fundamentals Growth
Kura Stock prices reflect investors' perceptions of the future prospects and financial health of Kura Oncology, and Kura Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kura Stock performance.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 429.95 M | ||||
| Shares Outstanding | 77.76 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 2.05 X | ||||
| EBITDA | (164.96 M) | ||||
| Net Income | (152.63 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.45 X | ||||
| Cash Flow From Operations | (124.82 M) | ||||
| Earnings Per Share | (2.35) X | ||||
| Market Capitalization | 868.62 M | ||||
| Total Asset | 448.94 M | ||||
| Retained Earnings | (721.44 M) | ||||
| Working Capital | 397.22 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
About Kura Oncology Performance
By analyzing Kura Oncology's fundamental ratios, stakeholders can gain valuable insights into Kura Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kura Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kura Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.40) | (0.38) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about Kura Oncology performance evaluation
Checking the ongoing alerts about Kura Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kura Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Biomea Fusions SWOT analysis clinical hold impacts diabetes drug stock |
- Analyzing Kura Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kura Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Kura Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kura Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kura Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kura Oncology's stock. These opinions can provide insight into Kura Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |